Key result
NAMPT rs1319501 CC+TC genotype linked to ~45% lower NAFLD risk versus TT genotype.
Why the study?
Given the role of visfatin in NAFLD, this study explored the potential association between the visfatin gene (NAMPT) and NAFLD.
Does the NAMPT rs1319501 'CC+TC' genotype reduce the risk of NAFLD compared to the 'TT' genotype?
Case-Control (n=312)
Does the NAMPT rs1319501 'CC+TC' genotype reduce the risk of NAFLD compared to the 'TT' genotype?
Carriers of the NAMPT rs1319501 'CC+TC' genotype have a significantly decreased risk of developing nonalcoholic fatty liver disease.
Background: Considering the role of visfatin in nonalcoholic fatty liver disease (NAFLD), a growing global epidemic, this article explores the potential association between the visfatin gene (NAMPT) and NAFLD. Methods: We used the PCR-restriction fragment length polymorphism method to genotype the rs1319501 promoter variant of the NAMPT gene in 154 patients with biopsy-proven NAFLD and 158 controls in this case–control genetic association study. Results: The ‘CC+TC’ genotype of NAMPT rs1319501 in comparison to the ‘TT’ genotype occurred less frequently in the cases with NAFLD than the controls, and the difference remained significant after adjustment for confounding factors (p = 0.029; odds ratio = 0.55; 95% CI = 0.31–0.82). Conclusion: This study showed, for the first time, that the carriers of the NAMPT rs1319501 ‘CC+TC’ genotype had a 45% decreased risk for NAFLD.
No takes yet. Share an insight, caveat, or question.
Mahmoudi et al. (2023) conducted a case-control in Nonalcoholic fatty liver disease (NAFLD) (n=312). NAMPT rs1319501 'CC+TC' genotype vs. 'TT' genotype was evaluated on Susceptibility to NAFLD (OR 0.55, 95% CI 0.31-0.82, p=0.029). Carriers of the NAMPT rs1319501 'CC+TC' genotype had a significantly decreased risk for NAFLD compared to the 'TT' genotype (OR 0.55; 95% CI 0.31-0.82; p=0.029).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: